AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca, in collaboration with Daiichi Sankyo and other partners, is conducting a Phase III clinical study titled ‘DESTINY-Endometrial01.’ The study aims to evaluate the efficacy of Trastuzumab Deruxtecan (T-DXd) combined with Rilvegostomig or Pembrolizumab as a first-line treatment for HER2-expressing, mismatch repair proficient endometrial cancer. This research is significant as it explores alternative therapies to standard chemotherapy, potentially improving patient outcomes.
The interventions being tested include T-DXd, an experimental drug, combined with either Rilvegostomig or Pembrolizumab, both administered intravenously. These combinations are compared against a standard chemotherapy regimen of Carboplatin and Paclitaxel with Pembrolizumab.
The study design is interventional, randomized, and follows a parallel assignment model. It is open-label, meaning both participants and researchers know which treatment is being administered, but sponsor personnel are blinded to efficacy data until the primary endpoint is reached. The primary purpose is treatment-focused, aiming to assess progression-free survival.
The study began on March 27, 2025, with an estimated primary completion date yet to be announced. The latest update was submitted on August 19, 2025, indicating ongoing recruitment and progress.
This clinical update could positively influence AstraZeneca’s stock performance by showcasing its commitment to innovative cancer treatments. As the study progresses, investor sentiment may improve, particularly if interim results are promising. Competitors in the oncology space will be closely monitoring these developments.
The DESTINY-Endometrial01 study is ongoing, with further details available on the ClinicalTrials portal.